Ambrx Biopharma EBIT

Ambrx Biopharma (AMAM) currently reports a EBIT of $-71M as of September 2023. That compares with $-73M in the prior-year period — up 3.0% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore Ambrx Biopharma's EBIT history and peer comparisons.

Ambrx Biopharma's EBIT increased from $-73M to $-71M — a 3.0% year-over-year increase (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Ambrx Biopharma's EBIT of $-71M is lower than the Healthcare sector average of $23B. That is roughly 100.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Ambrx Biopharma reported $-71M in EBIT as of September 2023. That compares with $-73M in the prior-year period — up 3.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-71M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for Ambrx Biopharma, and consider following AMAM for alerts when major investors trade the stock.